363 related articles for article (PubMed ID: 25941958)
1. Blinatumomab (Blincyto) for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 2015 May; 57(1468):e74-5. PubMed ID: 25941958
[TBL] [Abstract][Full Text] [Related]
2. Blinatumomab for the treatment of acute lymphoblastic leukemia.
Kaplan JB; Grischenko M; Giles FJ
Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
[TBL] [Abstract][Full Text] [Related]
3. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
4. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
5. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
6. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
8. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
12. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
[TBL] [Abstract][Full Text] [Related]
13. A closer look at blinatumomab.
Mattison RJ
Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
15. Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia.
Turner J; Schneider SM
Clin J Oncol Nurs; 2016 Apr; 20(2):165-8. PubMed ID: 26991709
[TBL] [Abstract][Full Text] [Related]
16. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.
Marini BL; Sun Y; Burke PW; Perissinotti AJ
J Oncol Pharm Pract; 2018 Jan; 24(1):67-73. PubMed ID: 27799606
[TBL] [Abstract][Full Text] [Related]
17. A review of blinatumomab, a novel immunotherapy.
Newman MJ; Benani DJ
J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Folan SA; Rexwinkle A; Autry J; Bryan JC
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Couturier MA; Thomas X; Raffoux E; Huguet F; Berthon C; Simand C; Gallego-Hernanz MP; Hicheri Y; Hunault Berger M; Saillard C; Leguay T; Loiseau C; Béné MC; Chevallier P
Leuk Lymphoma; 2021 Mar; 62(3):620-629. PubMed ID: 33153370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
